semaglutide diet plan what to eat and what to avoid Discover 43 semaglutide food ideas in 2026 foods to avoid when taking

Stable Gastric Pentadecapeptide BPC 157, Roberts Stomach Cytoprotection/Adaptive Cytoprotection/Organoprotection

Retatrutide vs tirzepatide vs semaglutide Category Receptor targets Retatrutide GLP-1 + GIP + Glucagon (triple) Tirzepatide GLP-1 + GIP (dual) Semaglutide GLP-1 only (single) Category Half-life Retatrutide ~6 days Tirzepatide ~5 days Semaglutide ~7 days Category Dose frequency Retatrutide Once weekly Tirzepatide Once weekly Semaglutide Once weekly Category Max studied dose Retatrutide 12 mg/week Tirzepatide 15 mg/week Semaglutide 2.4 mg/week Category Peak weight loss in trials Retatrutide -28.7% at 68 weeks (Phase 3 TRIUMPH-4) Tirzepatide -22.5% at 72 weeks (SURMOUNT-1) Semaglutide -15.8% at 68 weeks (STEP-1) Category FDA status (June 2026) Retatrutide Investigational, Phase 3 Tirzepatide Approved (obesity + T2D) Semaglutide Approved (obesity + T2D) Category Liver fat Retatrutide Up to 82% reduction (Phase 2 substudy) Tirzepatide Significant reduction Semaglutide Moderate reduction Category Unique angle Retatrutide Triple agonism may raise energy expenditure via glucagon pathway Tirzepatide Dual agonism balances effect and tolerability Semaglutide Longest clinical track record

This is why GLP-1 medications are generally not recommended for individuals with a personal or family history of Medullary Thyroid Cancer or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2), a genetic condition that predisposes people to certain endocrine tumours

It has no effect on lactating animals and pregnant animals Goats and Kids Composition of the biological product: The minimum rates for each dose (1 ml) are as follows

NSAIDs suppress the inflammatory signaling that BPC-157 modulates